Browsing: Lillys

detail *It has been translated using AI Eli Lilly’s obesity treatment “Munzaro” surpassed its rival product “Wigobi” in the cumulative number of prescriptions 10 months after it was released in Korea. Competition for high-dose products and next-generation new drugs is also in full swing as it quickly dominates the market with excellent weight loss effects.…

Eli Lilly (LLY, Financials), a pharmaceutical firm that focuses on diabetes, obesity and other chronic diseases, said it aims to petition for regulatory approval of retatrutide in the first quarter of 2027 after the medicine succeeded in two more phase 3 trials

Eli LillyLLY is a dominant player in the cardiometabolic market, backed by a strong and expanding GLP-1 portfolio. Its GLP-1 lineup includes Mounjaro and Zepbound (tirzepatide injections) for type II diabetes (T2D) and obesity, respectively, and the newly approved oral obesity therapy, Foundayo (orforglipron)

In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks

Mounjaro and Zepbound combined for $12.8 billion of Lilly’s $19.8 billion in first-quarter revenue

Eli Lilly (NYSE: LLY) commands a market capitalization of about $1.06 trillion, and that valuation was built largely on two drugs: Mounjaro and Zepbound. Investors talk about the drugmaker’s weight-loss and diabetes franchise constantly. But it’s worth pinning down what these medicines actually contribute, and the company’s most recent quarterly report gives a concrete answer